Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen: Apr 1, 2008

In an article published on March 25, entitled “Asuragen to Launch New Assay for FFPE Sample Profiling Next Month,” there are inaccuracies in certain statements attributed to Michael Wilson, a senior scientist at Asuragen, relating to regulatory requirements associated with patient sample acquisition (see BAN 3/25/2008).
Asuragen told BioArray News last week that it follows a policy that anyone considering working with samples of human origin consults with regulatory officials at their institutions and/or the appropriate federal agencies prior to initiating any sample acquisition or recruitment. 
Additionally, Asuragen clarified that it will be launching a service for analyzing gene expression using FFPE samples and does not intend for this service to be used for clinical diagnosis.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.